Your shopping cart is currently empty

Ginsenoside F4 exerts inhibitory effects on human lymphocytoma JK cells by inducing apoptosis. The mechanism of action involves mitochondrial dysfunction, increased Bax expression, and reduced Bcl-2 expression, together resulting in programmed cell death.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $81 | - | In Stock | |
| 5 mg | $228 | - | In Stock | |
| 10 mg | $342 | - | In Stock | |
| 25 mg | $572 | - | In Stock | |
| 50 mg | $813 | - | In Stock |
| Description | Ginsenoside F4 exerts inhibitory effects on human lymphocytoma JK cells by inducing apoptosis. The mechanism of action involves mitochondrial dysfunction, increased Bax expression, and reduced Bcl-2 expression, together resulting in programmed cell death. |
| In vitro | Methods: Ginsenoside F4 (8.15 μM, 65.19 μM, 130.38 μM) was used to treat Homo sapiens lymphoblastoma JK cells, and the expression of related proteins was detected by Western Blot. Results: Ginsenoside F4 induced apoptosis in Homo sapiens lymphoblastoma JK cells by downregulating Bcl-2 protein and upregulating Bax protein levels, which are key regulators associated with apoptosis, demonstrating its antitumor effects. [1] |
| Molecular Weight | 767.01 |
| Formula | C42H70O12 |
| Cas No. | 181225-33-2 |
| Smiles | C[C@]12[C@@]3(C)[C@@]([C@@H](\C(=C\CC=C(C)C)\C)CC3)([C@H](O)C[C@@]1([C@]4(C)[C@@]([C@@H](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O)[C@@H](CO)O5)C2)(C(C)(C)[C@@H](O)CC4)[H])[H])[H] |
| Relative Density. | 1.28 g/cm3 at 20℃ |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (52.15 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.